Physicochemical properties affecting retinal drug/coumarin-6 delivery from nanocarrier systems via eyedrop administration.

PURPOSE To elucidate the effect of physicochemical properties of nanocarrier systems on drug delivery efficiency to the retina by eyedrop administration in mice, rabbits, and monkeys. METHODS Submicron-sized liposomes (ssLips) of different particle size, cholesterol content, surface charge, and multilamellar vesicles (MLV) were prepared by the hydration METHOD Fluorescence probe (coumarin-6)-incorporated liposomes, lipid emulsions, and FITC-labeled polystyrene particles were used to investigate their intraocular behavior after eyedrop administration, using epifluorescence microscopy in mice, rabbits, and monkeys. RESULTS Delivery efficiency of fluorescent probes to the mouse retina from dropped liposomes was extensively improved by reducing their particle size (<600 nm) and cholesterol content, whereas negligible improvement was observed in the case of MLV. Furthermore, FITC-labeled polystyrene particles and coumarin-6-incorporated lipid emulsions showed an insufficient effect on retinal delivery in mice even if their size was controlled at 110 nm. The highest accumulation of the fluorescent probe in the retina was observed around 30 minutes with any type of ssLip used, followed by the prompt disappearance of their fluorescence within 120 minutes in mice. Changes in the fluorescence intensity of coumarin-6 in rabbits and monkeys were observed in a manner similar to that described in mice. Retinal flat-mount images suggest that coumarin-6 incorporated in ssLip diffused from the iris and ciliary body side to the optic disc side in the retina after eyedrop administration. CONCLUSIONS The delivery efficiency of coumarin-6 to the retina was altered depending on particle size, constituents, and rigidity. ssLips with appropriate features would be promising drug carriers for retinal delivery through eyedrops.

[1]  H. Takeuchi,et al.  Design and evaluation of a liposomal delivery system targeting the posterior segment of the eye. , 2009, Journal of controlled release : official journal of the Controlled Release Society.

[2]  Ashim K. Mitra,et al.  Recent Perspectives in Ocular Drug Delivery , 2009, Pharmaceutical Research.

[3]  C. Styles,et al.  FIRST VERSUS SECOND EYE INTRAVITREAL RANIBIZUMAB THERAPY FOR WET AMD , 2009, Retina.

[4]  R. Soares,et al.  Comparative effects of bevacizumab, ranibizumab and pegaptanib at intravitreal dose range on endothelial cells. , 2009, Experimental eye research.

[5]  P. Vavia,et al.  Diclofenac-loaded biopolymeric nanosuspensions for ophthalmic application. , 2009, Nanomedicine : nanotechnology, biology, and medicine.

[6]  Esther S. Kim,et al.  Human Scleral Diffusion of Anticancer Drugs from Solution and Nanoparticle Formulation , 2009, Pharmaceutical Research.

[7]  K. Csaky,et al.  Investigating the Movement of Intravitreal Human Serum Albumin Nanoparticles in the Vitreous and Retina , 2009, Pharmaceutical Research.

[8]  A. Badawi,et al.  Chitosan based nanocarriers for indomethacin ocular delivery , 2008, Archives of pharmacal research.

[9]  G. Abdelbary,et al.  Niosome-Encapsulated Gentamicin for Ophthalmic Controlled Delivery , 2008, AAPS PharmSciTech.

[10]  G. Noronha,et al.  Retinal vascular permeability suppression by topical application of a novel VEGFR2/Src kinase inhibitor in mice and rabbits. , 2008, The Journal of clinical investigation.

[11]  Y. Kawashima,et al.  A novel method for measuring rigidity of submicron-size liposomes with atomic force microscopy. , 2008, International journal of pharmaceutics.

[12]  S. Krishnakumar,et al.  Nanotechnology in ocular drug delivery. , 2008, Drug discovery today.

[13]  U. Kompella,et al.  Effect of circulation on the disposition and ocular tissue distribution of 20 nm nanoparticles after periocular administration , 2008, Molecular vision.

[14]  M. Ghorab,et al.  Nanosuspension as an ophthalmic delivery system for certain glucocorticoid drugs. , 2007, International journal of pharmaceutics.

[15]  A. Mitra,et al.  Novel approaches to retinal drug delivery , 2007, Expert opinion on drug delivery.

[16]  Hiroshi Murata,et al.  Involvement of ER stress in retinal cell death , 2007, Molecular vision.

[17]  Rania M. Hathout,et al.  Liposomes as an ocular delivery system for acetazolamide: In vitro and in vivo studies , 2007, AAPS PharmSciTech.

[18]  Clive G. Wilson,et al.  Topical and systemic drug delivery to the posterior segments. , 2005, Advanced drug delivery reviews.

[19]  U. Kompella,et al.  Size‐dependent disposition of nanoparticles and microparticles following subconjunctival administration , 2005, The Journal of pharmacy and pharmacology.

[20]  M. Gremião,et al.  Colloidal carriers for ophthalmic drug delivery. , 2005, Current drug targets.

[21]  J. Irache,et al.  Pegylated nanoparticles based on poly(methyl vinyl ether-co-maleic anhydride): preparation and evaluation of their bioadhesive properties. , 2005, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[22]  D. Aggarwal,et al.  Vesicular systems in ocular drug delivery: an overview. , 2004, International journal of pharmaceutics.

[23]  Daniel F. Martin,et al.  Endophthalmitis after ganciclovir implant in patients with AIDS and cytomegalovirus retinitis. , 2003, American journal of ophthalmology.

[24]  M. Iliev,et al.  In vivo pachymetry in normal eyes of rats, mice and rabbits with the optical low coherence reflectometer , 2003, Vision Research.

[25]  T. Vandamme Microemulsions as ocular drug delivery systems: recent developments and future challenges , 2002, Progress in Retinal and Eye Research.

[26]  F. Nielloud,et al.  Emulsions in Health Care Applications—An Overview , 2002 .

[27]  D. Maurice,et al.  Review: practical issues in intravitreal drug delivery. , 2001, Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics.

[28]  C. Chiang,et al.  Acyclovir-containing liposomes for potential ocular delivery. Corneal penetration and absorption. , 2000, Journal of controlled release : official journal of the Controlled Release Society.

[29]  J. Lim,et al.  Visual and anatomic outcomes associated with posterior segment complications after ganciclovir implant procedures in patients with AIDS and cytomegalovirus retinitis. , 1999, American journal of ophthalmology.

[30]  M. Alonso,et al.  Improved Ocular Bioavailability of Indomethacin by Novel Ocular Drug Carriers , 1996, The Journal of pharmacy and pharmacology.

[31]  H. Utsumi,et al.  Motional state of spin-labeled stearates in lecithin-cholesterol liposomes and their incorporation capability. , 1976, Chemical & pharmaceutical bulletin.

[32]  U. Kompella,et al.  Modeling of corneal and retinal pharmacokinetics after periocular drug administration. , 2008, Investigative ophthalmology & visual science.

[33]  S. Benita,et al.  Pilocarpine incorporated into a submicron emulsion vehicle causes an unexpectedly prolonged ocular hypotensive effect in rabbits. , 1994, Journal of ocular pharmacology.